Full-Time

Validation Engineer

Pharmaceutical Sterile Manufacturing

Nivagen Pharmaceuticals

Nivagen Pharmaceuticals

51-200 employees

Develops, acquires, and markets generic drugs

Compensation Overview

$90k - $105k/yr

+ Bonus

Sacramento, CA, USA

In Person

Must reside within ~40 miles of Sacramento metropolitan region.

Bachelor's

Category
QA & Testing (1)

Get referred to Nivagen Pharmaceuticals

See people who can refer or advise you

Requirements
  • Bachelor's degree or Diploma in Pharmaceuticals, or a related field.
  • Minimum 2 years of experience in a pharmaceutical manufacturing or validation role, with a focus on sterile manufacturing (e.g., aseptic processing, sterile filling, isolator, autoclave sterilization).
  • Strong understanding of cGMP, FDA, EMA, ISO standards, and other relevant regulatory requirements.
  • Experience with equipment validation (e.g., filling machines, autoclaves, and HVAC systems) and process validation.
  • Familiarity with the documentation requirements for validation, including protocol development, execution, and report writing.
  • Must live or be willing to move to Sacramento Metropolitan Region (Approx. 40 miles’ radius).
  • Willing to travel as needed basis to other manufacturing sites for vendor support.
Responsibilities
  • Qualification of Equipment and Systems: Perform or oversee the Installation Qualification (IQ), Operational Qualification (OQ), and Performance Qualification (PQ) of new and existing equipment and systems.
  • Qualification of equipment in sterile manufacturing facility (e.g., aseptic processing, sterile filling, isolators, autoclave sterilization).
  • Ensure compliance with regulatory requirements for equipment qualification and validation.
  • Knowledge of validation equipment like Kaye validator, temperature and RH data loggers etc.
  • Validation Documentation and Protocols: Prepare and review validation reports to ensure they meet regulatory and company requirements.
  • Maintain traceability of validation activities and ensure all validation records are accurately documented, maintained, and stored.
  • Process Validation and Cleaning Validation: Conduct and manage process validation studies to confirm the sterility and quality of pharmaceutical products.
  • Work with cross-functional teams (e.g., production, quality control, engineering) to optimize manufacturing processes and ensure consistency and repeatability.
  • Support the development and implementation of new processes, ensuring that they are validated per regulatory requirements.
  • Knowledge of cleaning validation will be an added advantage
  • Perform any additional tasks as assigned by the Validations Lead
Desired Qualifications
  • Knowledge of cleaning validation will be an added advantage
Nivagen Pharmaceuticals

Nivagen Pharmaceuticals

View

Nivagen Pharmaceuticals develops, acquires, and sells generic prescription drugs and OTC products for the North American market. It leverages global partnerships with FDA-approved manufacturing facilities to deliver high-quality, affordable products and collaborates with the world’s best CROs and CRAMs to develop and manufacture niche generics. The company supports small FDA-qualified manufacturers entering the U.S. market and differentiates itself through its ability to launch new generic products and its strong sales and marketing team, rather than relying on a single manufacturing or development approach. Revenue comes from product development, co-development, acquisitions, in-licensing, and providing sales and marketing services. Nivagen aims to grow its portfolio by forging CRO/CRAM partnerships, acquiring existing products, and expanding its product lineup to capture a larger share of the evolving generic and OTC market in North America.

Company Size

51-200

Company Stage

Growth Equity (Venture Capital)

Total Funding

$26M

Headquarters

Sacramento, California

Founded

2009

Get referred to Nivagen Pharmaceuticals

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • PAI Pharma's January 6, 2026 acquisition brings Olympus-backed capital and distribution.
  • Owning the Sacramento site after February 2026 strengthens expansion and regulatory control.
  • Shortage-sensitive injectable demand supports faster commercialization for Nivagen's RTU pipeline.

What critics are saying

  • Nivagen's zinc oxide Class II recall, started October 31, 2025, remains ongoing.
  • California recalled atorvastatin tablets in September 2024 for a carbamazepine mix-up.
  • Repeated cGMP failures or sterile contamination would trigger FDA shutdowns and destroy hospital trust.

What makes Nivagen Pharmaceuticals unique

  • Sacramento's 100,000-square-foot sterile facility makes Nivagen unusually domestic for injectables.
  • Nivagen built over 20 ready-to-use sterile injectables before PAI Pharma's January 2026 acquisition.
  • Its 503B compounding and CDMO services target shortage-driven hospital demand directly.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Paid Time Off

401 (k) savings plan

Growth & Insights and Company News

Headcount

6 month growth

-4%

1 year growth

-4%

2 year growth

-7%
PE Hub
Jan 6th, 2026
Olympus-backed PAI Pharma picks up Nivagen Pharmaceuticals

Olympus-backed PAI Pharma picks up Nivagen Pharmaceuticals. Headquartered in Greenville, South Carolina, PAI is a developer, manufacturer and marketer of oral liquid medicines. * Nivagen operates an aseptic manufacturing facility in Sacramento, California, designed to support the production of IV bags, vials, prefilled syringes, and cartridges * Nivagen was founded in 2009 PAI Pharma, which is backed by Olympus Partners, has acquired Nivagen Pharmaceuticals, Inc, a Sacramento, California-based pharmaceutical company. No financial terms were disclosed. Gain instant access to our expert editorial analysis and in-depth insight. Already have an account? Sign in.

Benzinga
Jan 6th, 2026
PAI Pharma acquires Nivagen to expand US sterile injectable manufacturing amid persistent drug shortages

PAI Pharma, a portfolio company of Olympus Partners, has acquired Nivagen Pharmaceuticals, a California-based pharmaceutical company specialising in ready-to-use sterile injectables. The deal expands PAI's domestic manufacturing capabilities and addresses persistent drug shortages in the US healthcare system. Nivagen operates a state-of-the-art aseptic manufacturing facility in Sacramento, producing IV bags, vials, prefilled syringes and cartridges. The company brings over 20 injectable products to complement PAI's existing sterile portfolio of approximately 10 products in development and four on the market. The acquisition aligns with growing efforts to reshore pharmaceutical production and reduce reliance on foreign supply chains. PAI Pharma was advised by Bourne Partners, Kirkland & Ellis and KPMG, whilst Olympus Partners provided backing for the transaction.

Private Equity Info
Aug 22nd, 2022
Corbel Capital Partners invests into Nivagen Pharmaceuticals, Inc.

Corbel Capital Partners invested in Nivagen Pharmaceuticals (Sacramento, CA, US), a specialty pharmaceuticals business that develops and sells generic and branded prescription drugs.